Reports Q1 revenue $11.426M vs $14.681M last year. “I am pleased to report that we have filed our Form 10-Q quarterly reports for the first and the second quarters 2025, as a result of which we have regained compliance with the Nasdaq Listing Rule 5250(c)(1). This is another important step for Celularity (CELU), as it comes on the heels of the recently announced retirement of all $32.0 million of the Company’s senior secured debt plus $9.6 million in associated unpaid interest, the Asset Purchase Agreement and a License Agreement with Celeniv Pte. Ltd., and an internal restructuring that includes establishing operating subsidiaries for each of its functional business units,” said Robert J. Hariri, M.D., Ph.D., Celularity’s Chairman and CEO.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELU:
- Celularity Achieves Nasdaq Compliance with Recent Filing
- Celularity receives noncompliance notice from Nasdaq
- Celularity Sells IP to Celeniv, Reduces Debt
- Celularity’s Strategic Positioning and Financial Restructuring Drive Buy Rating
- Celularity completes balance sheet restructuring, retires $41.6M in debt